Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group

Background: Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm of infants and toddlers. Upfront therapies typically include high-dose cytarabine or azacitidine, but the only definitive treatment is hematopoietic stem cell transplantation (HSCT). While HSCT cures ~50...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.74-74
Hauptverfasser:	Stieglitz, Elliot, Lee, Alex, Angus, Steven P., Davis, Christopher, Barkauskas, Donald, Hall, David, Kogan, Scott C., Meyer, Julia, Rhodes, Steven D., Xuei, Xiaoling, Shannon, Kevin, Loh, Mignon L., Fox, Elizabeth, Weigel, Brenda J.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!